Bill > HR2639

This bill, the Electrodiagnostic Medicine Patient Protection and Fraud Elimination Act of 2023, aims to amend the Social Security Act to establish additional requirements for electrodiagnostic services under the Medicare program. The key provisions of the bill include: 1. No Medicare payment for electrodiagnostic services (nerve conduction studies and needle electromyography tests) furnished at facilities that are not accredited by an organization specified by the Secretary of Health and Human Services (HHS). 2. The Secretary must, within 2 years, specify accrediting organizations that require facilities to meet certain quality and safety standards, such as having a quality assurance program, using appropriate devices, and ensuring qualified personnel perform and interpret the tests. 3. The Secretary must establish an advisory committee, the National Electrodiagnostic Services Advisory Committee, to provide recommendations on the accreditation requirements, regulations, and the selection of accrediting organizations. The overall goal of the bill is to improve the reliability, safety, and accuracy of electrodiagnostic services provided to Medicare beneficiaries, as well as to address emerging waste, fraud, and abuse schemes in this area of healthcare.